Sign in
Not yet recruitingPhase 1

Nicotinamide (vitamin B3) for Leber's hereditary optic neuropathy, a small early study

Tests nicotinamide in people recently affected by Leber's hereditary optic neuropathy.

Key facts

Who runs it
University Hospital, Angers
Where
France1 site in 1 countryChoose a country to see its sites
Registry title
Pilot Study of the Efficacy of Nicotinamide (Vitamin B3) in Leber's Hereditary Optic Neuropathy
Status
Not yet recruiting
Phase
Phase 1
People taking part
13 people, planned
Started
Apr 2026
Expected to end
Apr 2028
Type of study
Interventional
Treatments tested
  • Nicotinamide treatment
Record updated
18 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 16 or older with Leber Hereditary Optic Neuropathy (LHON), an inherited disease causing sudden vision loss. Symptoms must have started less than 18 months ago.

Age
16 years or older
Sex
All sexes
Disease stage
LHON with symptoms that started less than 18 months before joining. Carriers of the gene change without symptoms cannot join.
Earlier treatment
No nicotinamide treatment for at least 3 months before joining. No current idebenone or idebenone in the last 3 months. No earlier gene therapy.
Biomarker or test result
Confirmed mitochondrial DNA mutation m.11778G>A or m.3460G>A.

Main reasons for not taking part

  • LHON caused by other mitochondrial DNA mutations or nuclear DNA mutations
  • Severe other eye disease, such as advanced glaucoma or retina disease
  • High liver enzymes (ASAT and/or ALAT > 2× upper normal limit)
  • Pregnant, breastfeeding or women who recently gave birth
  • Allergy or intolerance to lactose or galactose, or a known reason not to take nicotinamide

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Patients aged 16 years or older
  • Diagnosis of Leber Hereditary Optic Neuropathy (LHON) due to a confirmed mitochondrial DNA mutation m.11778G>A or m.3460G>A
  • Onset of LHON symptoms less than 18 months before inclusion
  • Naïve to nicotinamide treatment for at least 3 months prior to inclusion
  • Able to take oral medication and comply with study procedures
  • Affiliated with or beneficiary of a social security system
  • Signed informed consent (or parental consent for minors; assent for minors when applicable)

Who cannot take part

  • LHON onset more than 18 months before inclusion
  • Current or recent treatment with idebenone (within 3 months)
  • Patients treated with gene therapy
  • Elevated liver enzymes (ASAT and/or ALAT > 2× upper normal limit) at screening or within 2 months prior to inclusion
  • Severe associated ophthalmologic disease (e.g., advanced glaucoma, retinal pathology)
  • Known contraindication to nicotinamide or allergy/intolerance to lactose or galactose
  • Subjects under legal protection or psychiatric care under constraint
  • Any condition that, in the investigator's judgment, could compromise patient safety or study integrity
  • Asymptomatic carriers of m.11778G>A or m.3460G>A mutations (no clinical LHON)
  • LHON due to other mitochondrial DNA mutations or nuclear DNA mutations
  • Pregnant, breastfeeding, or postpartum women
  • Persons deprived of liberty by judicial or administrative decision
  • Unable to provide informed consent
  • Participation in another interventional study affecting LHON management

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Leber Hereditary Optic Neuropathy (LHON) is a rare genetic disease that causes sudden and severe vision loss, usually in young adults. It is linked to mutations in mitochondrial DNA that impair energy production in retinal ganglion cells, leading to degeneration of the optic nerve. Currently, treatment options are very limited and often ineffective. Recent research has shown that patients with LHON have lower levels of nicotinamide (vitamin B3), a key molecule for mitochondrial energy metabolism. Nicotinamide is a precursor of NAD, an essential cofactor for cellular energy production. Experimental studies and clinical trials in related optic nerve diseases suggest that nicotinamide may protect retinal ganglion cells. Our hypothesis is that supplementation with high-dose nicotinamide could restore NAD levels, support mitochondrial activity, and help preserve or improve vision in LHON. This pilot study will evaluate the effectiveness and safety of oral nicotinamide (2 grams per day for 12 months) in patients who developed LHON within the past 18 months and carry one of the two most severe mutations (m.11778G>A or m.3460G>A). The main goal is to measure changes in visual acuity over time using standardized eye charts. Secondary objectives include assessing visual fields, retinal structure by optical coherence tomography (OCT), blood nicotinamide levels, and quality of life. Liver function will be monitored to ensure safety. If this study shows promising results, it could pave the way for a larger randomized trial and ultimately offer a new therapeutic option.

The group in the trial

  • NicotinamideTreatment being tested

    Treatment: Nicotinamide treatment

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
NICOLHON - Pilot Study of the Efficacy of Nicotinamide (Vitamin B3) in Leber's Hereditary Optic Neuropathy
Plain-language title
Nicotinamide (vitamin B3) for Leber's hereditary optic neuropathy, a small early studyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
18 December 2025